← Product Code [NOE](/submissions/IM/subpart-f%E2%80%94immunological-test-systems/NOE) · K062234 # MODIFICATION TO DIADEXUS PLAC TEST (K062234) _Diadexus, Inc. · NOE · Sep 11, 2006 · Immunology · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/CH/subpart-f%E2%80%94immunological-test-systems/NOE/K062234 ## Device Facts - **Applicant:** Diadexus, Inc. - **Product Code:** [NOE](/submissions/IM/subpart-f%E2%80%94immunological-test-systems/NOE.md) - **Decision Date:** Sep 11, 2006 - **Decision:** SESE - **Submission Type:** Special - **Regulation:** 21 CFR 866.5600 - **Device Class:** Class 2 - **Review Panel:** Immunology ## Indications for Use The diaDexus PLAC® test is an enzyme immunoassay for the quantitative determination of Lp-PLA2 (lipoprotein-associated phospholipase A2) in human plasma and serum, to be used in conjunction with clinical evaluation and patient risk assessment as an aid in predicting risk for coronary heart disease, and ischemic stroke associated with atherosclerosis. ## Device Story The diaDexus PLAC® test is an enzyme immunoassay (EIA) kit used to quantify Lp-PLA2 levels in human plasma or serum samples. The device utilizes a sandwich immunoassay principle with two monoclonal antibodies: 2C10 (coated on microwell strips) and 4B4 (conjugated to horseradish peroxidase). The test is performed in a clinical laboratory setting. The operator adds samples and reagents to the microwells; the resulting absorbance is measured. Lp-PLA2 concentration is determined by interpolating sample absorbance against a standard curve generated from provided calibrators using point-to-point curve fitting software. Results assist clinicians in assessing patient risk for coronary heart disease and ischemic stroke associated with atherosclerosis. The test is intended for use in conjunction with other clinical evaluations. ## Clinical Evidence No new clinical data was generated. The device relies on performance characteristics established for the predicate device (k050523). Analytical performance includes a detection limit of 2.4 ng/mL, linearity range of 120-782 ng/mL, and intra-assay precision of 4.3-6.3% CV. ## Technological Characteristics Sandwich enzyme immunoassay. Components: monoclonal anti-Lp-PLA2 (2C10) coated microwells, monoclonal anti-Lp-PLA2 (4B4) horseradish peroxidase conjugate, and recombinant Lp-PLA2 calibrators. Quantitative measurement via absorbance. Software-based point-to-point curve fitting for concentration interpolation. Single-use microwell strips. ## Regulatory Identification A low-density lipoprotein immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the low-density lipoprotein in serum and other body fluids. Measurement of low-density lipoprotein in serum may aid in the diagnosis of disorders of lipid (fat) metabolism and help to identify young persons at risk from cardiovascular diseases. ## Predicate Devices - PLAC® test (k050523) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ SEP 1 1 2006 diaDexus, Inc. PLAC® Test Special 510(k) k062234 ## 510(k) Summary diaDexus PLAC® Test This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92. The assigned 510(k) number is: k062234 General Information | Name and Address of Applicant: | diaDexus, Inc.
343 Oyster Point Blvd.
South San Francisco, CA 94080 | |--------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------| | Device Trade Name: | diaDexus PLAC® test | | Generic Name: | Enzyme Immunoassay for the Quantitative
Determination of Lp-PLA2 (Lipoprotein-
Associated Phospholipase A2) in Human
Plasma and Serum | ## Intended Use The diaDexus PLAC® test is an enzyme immunoassay for the quantitative determination of Lp-PLA2 (lipoprotein-associated phospholipase A2) in human plasma and serum, to be used in conjunction with clinical evaluation and patient risk assessment as an aid in predicting risk for coronary heart disease, and ischemic stroke associated with atherosclerosis. ## Device Description The diaDexus PLAC® test kit contains Lp-PLA2 calibrators, monoclonal anti-Lp-PLA2 (4B4) antibody conjugated to horseradish peroxidase, monoclonal anti-Lp-PLA2 (2C10) antibody-coated microwell strips with a stripwell frame, various buffers and related reagents, and a package insert. Each stripwell can be used for performing only one set of tests (i.e. single use). One plate may accommodate up to 40 clinical samples when assayed in duplicate. The kit expiration date and storage conditions are indicated on the package. {1}------------------------------------------------ The diaDexus PLAC® test is based on the standard principle of a sandwich enzyme immunoassay using two specific monoclonal antibodies. A set of LD-PLA2 calibrators is used to plot a standard curve of absorbance (y-axis) versus Lp-PLA2 concentration in ng/mL (x-axis) from which the Lp-PLA2 concentration in the test sample can be determined. The concentration of Lp-PLA2 in each sample and control is then interpolated from the standard curve using a point-to-point curve fit with appropriate calibration curve fitting software. #### Characterization of Rare Reagents #### Antigen The antigen used in the diaDexus enzyme immunoassay PLAC® test is purified recombinant Lp-PLA2 (DDX-RA). Antigen preparations were characterized using SDS-polyacrylamide gels under reducing and non-reducing conditions and Western blot analysis using an anti-Lp-PLA2 antibody, to demonstrate consistency with the molecular weight of the antigen reported in the literature. #### Antibodies The monoclonal anti-Lp-PLA2 antibodies used in the preparation of the coated microwell strips (2C10) and conjugate (4B4) were characterized for purity and reactivity in a series of procedures including Paragon gel electrophoresis, SDS-PAGE, size exclusion chromatography, isotyping and enzyme immunoassay. These results demonstrated that the monoclonal antibodies bind to the Lp-PLA2 antigen quantitatively and specifically. #### Performance Characteristics - Analytical #### Analytical Sensitivity (Detection Limit) The minimum detection limit is 2.4 ng/mL, as calculated by interpolation of the mean plus two standard deviations of 16 replicates of the 0 ng/mL Lp-PLA2 calibrator. #### Linearity/Assay Range 120 - 782 ng/mL {2}------------------------------------------------ ## Interfering Substances No appreciable interference from the addition of the following substances at the noted concentrations: - Total Albumin ~6500 mg/dL . - . Bilirubin 20 mg/dL - Cholesterol . 500 mg/dL - Hemoglobin . 1250 mg/dL - Triglycerides � 3000 mg/dL #### Precision Intra-assay precision (n=80) ranged from 4.3 %CV to 6.3 %CV throughout assay range. Total precision (n=80) ranged from 5.7 %CV to 11.0 %CV throughout assay range. ## Correlation The modified PLAC test compared to the cleared PLAC test in a correlation regression resulted in an r value of 0.91 with a slope of 1.02. ## Performance Characteristics – Clinical No new clinical data was generated. The modified PLAC test has the same performance characteristics and clinical utility as the cleared PLAC test (k050523). {3}------------------------------------------------ Image /page/3/Picture/0 description: The image shows the text "DEPARTMENT OF HEALTH & HUMAN SERVICES". The text is in all caps and is in a bold, sans-serif font. The text is centered horizontally and vertically in the image. The background of the image is white. Public Health Service SEP 1 1 2006 Food and Drug Administration 2098 Gaither Road Rockville MD 20850 Robert L. Wolfert, Ph.D. Executive Vice President of Diagnostics diaDexus, Inc. 343 Oyster Point Blvd. South San Francisco, CA 94080 Re: k062234 Trade/Device Name: diaDexus PLAC® Test Regulation Number: 21 CFR 866.5600 Regulation Name: Low-density lipoprotein immunological test system Regulatory Class: Class II Product Code: NOE Dated: August 1, 2006 Received: August 23, 2006 Dear Dr. Wolfert: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). Image /page/3/Picture/10 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is circular and contains the words "DEPARTMENT OF HEALTH & HUMAN SERVICES . USA" around the perimeter. Inside the circle is an abstract symbol that resembles an eagle or bird with stylized lines representing its wings and body. {4}------------------------------------------------ Page 2 - This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html. Sincerely yours, Alberto G Alberto Gutierrez, Ph.D. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health Enclosure {5}------------------------------------------------ # Indications for Use 510(k) Number: k062234 Device Name: diaDexus PLAC® Test Indications For Use: The diaDexus PLAC® test is an enzyme immunoassay for the quantitative determination of Lp-PLA2 (lipoprotein-associated phospholipase A2) in human plasma and serum, to be used in conjunction with clinical evaluation and patient risk assessment as an aid in predicting risk for coronary heart disease, and ischemic stroke associated with atherosclerosis. Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use (21 CFR 801 Subpart C) ## (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD) Division Sign-Off Office of in Vitro Diagnostic Device Evaluation and Safety 510(k) K062234 Page 1 of 1 --- **Source:** [https://fda.innolitics.com/submissions/CH/subpart-f%E2%80%94immunological-test-systems/NOE/K062234](https://fda.innolitics.com/submissions/CH/subpart-f%E2%80%94immunological-test-systems/NOE/K062234) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com